A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026.

Nasal vaccines offer convenience and another option for those wary of needles, but traditional vaccines are best for young ...

Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...

Scientists discover microgravity in space could help fight drug-resistant superbugs by creating unique viral mutations, ...

Ushikuvirus, a newly identified giant virus, showcases unique cytopathic effects and structural features, enhancing knowledge of viral evolution and diversity.

A new 10-year regional study reveals that adults living with both HIV and hepatitis B virus across the Asia-Pacific face ...

By studying large language models as if they were living things instead of computer programs, scientists are discovering some ...

Report Ocean’s comprehensive analysis delves into the Respiratory Syncytial Virus (RSV) landscape, encompassing historical data, forecasted epidemiology, and market trends globally. The report ...

This video ranks the seven living gar species based on size, appearance, geographic range, and unique evolutionary traits. Viewers learn how each species adapted to its environment while retaining ...